摘要
目的观察马来酸罗格列酮与磺脲类/二甲双胍联合应用对2型糖尿病(T2DM)患者血浆内皮素(ET)、微量白蛋白尿的影响。方法68例2型糖尿病患者进行为期24周的马来酸罗格列酮联合磺脲类/二甲双胍治疗,观察血浆内皮素(ET)、微量白蛋白尿、空腹血糖(FBG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)、胰导素抵抗指数(IRA)、血脂、血压的治疗前后的变化。结果马来酸罗格列酮治疗24周后血浆内皮素(ET)、微量白蛋白尿、空腹血糖、糖化血红蛋白、空腹胰岛素水平均有显著下降,胰岛素抵抗指数(HOMA指数)下降;总胆固醇(TC)、低密度脂蛋白(LDL-C)明显降低。结论马来酸罗格列酮明显降低T2DM患者空腹血浆ET水平,有益于改善糖尿病血管并发症;减少尿微量白蛋白预防糖尿病肾病。
Objective To evaluate the clinical efficacy of rosiglitazone and sulfonylurea/metformine on plasma endothelin levels and microalbuminuria in type 2 diabetes mellitus patients. Methods Sixty-eight type 2 diabetic patients were treated with rosiglitazone combined with either suffonylurea or metformin , and were assayed for fasting plasma glucose, fasting plasma endothelin levels and microalbuminuria, fasting plasma insulin, blood lipids, glycosylated hemoglobin, liver and kidney functions before and after treatment for 24 weeks. Results After treatment, plasma endothelin levels and microalbuminuria, fasting plasma glucose, fasting plasma insulin, and homeostasis model assessment decreased very significantly （ P 〈 0.01 ） ;total cholesterol and low-density lipoprotein C decreased significiantly. Condusions In patients with type 2 diabetes mellitus, rosiglitazones reduces fasting plasma endothelin levels, conductive to improving vascular complications, lowers microalbuminuria levels, and prevents early diabetic nepropathy.
出处
《武警医学》
CAS
2005年第8期599-601,共3页
Medical Journal of the Chinese People's Armed Police Force
